Evidence map›Paper›PMID 37932788›Full record

ArticleJournal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance2023

Effect of etelcalcetide versus alfacalcidol on left ventricular function and feature-tracking cardiac magnetic resonance imaging in hemodialysis-a post-hoc analysis of a randomized, controlled trial.

Katharina Dörr, Andreas Kammerlander, Francesco Lauriero, Matthias Lorenz, Rodrig Marculescu, Dietrich Beitzke

2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03182699 phase4completednot on this map

Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients: A Randomized Controlled Trial

TypeinterventionalSponsorRainer OberbauerRan2017 to 2019Enrolled62ConditionsSecondary Hyperparathyroidism, Chronic Kidney Disease Requiring Chronic Dialysis, Left Ventricular HypertrophyArmscardiac MRI, echocardiography with strain, Laboratory tests, Body composition monitoring, lung ultrasound
NCT07270367 phase3not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Finerenone and Cardiac Remodeling: A Randomized, Double- Blind, Placebo-Controlled Study to Evaluate The Effects of Finerenone on Ventricular Remodeling

TypeinterventionalSponsorSubodh VermaRan2025 to 2030Enrolled156ConditionsHeart FailureArmsFinerenone, Placebo
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Katharina DörrDepartment of Nephrology, Medical University of Vienna, Vienna, Austria.
Andreas KammerlanderDepartment of Cardiology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. andreas.kammerlander@meduniwien.ac.at.ORCID 0000-0002-7632-9879
Francesco LaurieroDepartment of Radiological and Hematological Science, Section of Radiology, Università Cattolica del Sacro Cuore, Rome, Italy.
Matthias LorenzVienna Dialysis Center, Vienna, Austria.
Rodrig MarculescuDepartment of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
Dietrich BeitzkeDepartment of Biomedical Imaging and Image-Guided Therapy, Division of Cardiovascular and Interventional Radiology, Medical University of Vienna, Vienna, Austria.
Medical University of Vienna · ATUniversità Cattolica del Sacro Cuore · IT

Funding

Amgen IIP #20167811
6 · The paper itself

Abstract

backgroundCalcimimetic therapy with etelcalcetide (ETEL) has been shown to attenuate the advancement of left ventricular (LV) hypertrophy in hemodialysis patients measured by cardiac magnetic resonance (CMR). The aim of the study was to evaluate whether this effect is accompanied by alterations in LV function and myocardial composition.

methodsThis was a post-hoc analysis of a randomized-controlled trial of ETEL versus Alfacalcidol (ALFA) in 62 hemodialysis patients. LV function was assessed using LV ejection fraction (LVEF) and LV global longitudinal strain (GLS) on feature-tracking (FT) CMR. Myocardial tissue characteristics were analyzed using parametric T1 and T2 mapping.

resultsOf the total study cohort (n = 62), 48 subjects completed both CMR scans with sufficient quality for FT analysis. In the one-year follow-up, LV GLS deteriorated in the ALFA group, whereas the ETEL group remained stable (LV GLS change: + 2.6 ± 4.6 versus + 0.3 ± 3.8; p = 0.045 when adjusting for randomization factors and baseline LV GLS). We did not observe a difference in the change of LVEF between the two groups (p = 0.513). The impact of ETEL treatment on LV GLS over time remained significant after additional adjustment for the change in LV mass during the study period. ETEL treatment did not significantly affect other CMR parameters. There were no changes in myocardial composition between treatment groups (T1 time change: + 15 ± 42 versus + 10 ± 50; p = 0.411; T2 time change: - 0.13 ± 2.45 versus - 0.70 ± 2.43; p = 0.652).

conclusionsIn patients undergoing hemodialysis, treatment with ETEL was protective against deterioration of LV longitudinal function, as evaluated through FT CMR, when compared to the control therapy of ALFA. This effect was not mediated by the change in LV mass. Trial registration URL: https://clinicaltrials.gov/ct2/show/NCT03182699 . Unique identifier: NCT03182699.

Indexed as

Magnetic Resonance Imaging, CineVentricular Function, LeftHumansHydroxycholecalciferolsHypertrophy, Left VentricularMagnetic Resonance ImagingPeptidesPredictive Value of TestsRandomized Controlled Trials as TopicRenal DialysisStroke Volumealfacalcidoletelcalcetide hydrochlorideHydroxycholecalciferolsPeptidesCardiac magnetic resonance imagingEtelcalcetideGlobal longitudinal strainHemodialysisLeft ventricular function

Identifiers

PMID37932788
PMCPMC10626812
OpenAlexW4388413143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.